

Kazuhide Watanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4948038/publications.pdf>

Version: 2024-02-01

45
papers

2,271
citations

236612

25
h-index

243296

44
g-index

50
all docs

50
docs citations

50
times ranked

2580
citing authors

#	ARTICLE	IF	CITATIONS
1	Coordinate control of basal epithelial cell fate and stem cell maintenance by core EMT transcription factor Zeb1. <i>Cell Reports</i> , 2022, 38, 110240.	2.9	24
2	SkewC: Identifying cells with skewed gene body coverage in single-cell RNA sequencing data. <i>IScience</i> , 2022, 25, 103777.	1.9	4
3	Effective pseudo-labeling based on heatmap for unsupervised domain adaptation in cell detection. <i>Medical Image Analysis</i> , 2022, 79, 102436.	7.0	8
4	Interpretable, Scalable, and Transferrable Functional Projection of Large-Scale Transcriptome Data Using Constrained Matrix Decomposition. <i>Frontiers in Genetics</i> , 2021, 12, 719099.	1.1	2
5	Nfatc1's Role in Mammary Epithelial Morphogenesis and Basal Stem/progenitor Cell Self-renewal. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2021, 26, 357-365.	1.0	1
6	Integrated Single-Cell Transcriptomics and Chromatin Accessibility Analysis Reveals Regulators of Mammary Epithelial Cell Identity. <i>Cell Reports</i> , 2020, 33, 108273.	2.9	36
7	The NF- κ B regulator $\text{I}\kappa\text{B}^2$ exhibits different molecular interactivity and phosphorylation status from $\text{I}\kappa\text{B}\alpha$ in an IKK2-catalysed reaction. <i>FEBS Letters</i> , 2020, 594, 1532-1549.	1.3	4
8	Combinatorial perturbation analysis reveals divergent regulations of mesenchymal genes during epithelial-to-mesenchymal transition. <i>Npj Systems Biology and Applications</i> , 2019, 5, 21.	1.4	65
9	OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineages. <i>Scientific Reports</i> , 2019, 9, 6490.	1.6	38
10	NAPE-PLD controls OEA synthesis and fat absorption by regulating lipoprotein synthesis in an <i>in vitro</i> model of intestinal epithelial cells. <i>FASEB Journal</i> , 2019, 33, 3167-3179.	0.2	10
11	Overexpression of Transcription Factor Ovol2 in Epidermal Progenitor Cells Results in Skin Blistering. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1805-1808.	0.3	7
12	An Ovol2-Zeb1 Mutual Inhibitory Circuit Governs Bidirectional and Multi-step Transition between Epithelial and Mesenchymal States. <i>PLoS Computational Biology</i> , 2015, 11, e1004569.	1.5	245
13	Integrative ChIP-seq/Microarray Analysis Identifies a CTNNB1 Target Signature Enriched in Intestinal Stem Cells and Colon Cancer. <i>PLoS ONE</i> , 2014, 9, e92317.	1.1	41
14	The Co-factor of LIM Domains (CLIM/LDB/NLI) Maintains Basal Mammary Epithelial Stem Cells and Promotes Breast Tumorigenesis. <i>PLoS Genetics</i> , 2014, 10, e1004520.	1.5	13
15	Mammary Morphogenesis and Regeneration Require the Inhibition of EMT at Terminal End Buds by Ovol2 Transcriptional Repressor. <i>Developmental Cell</i> , 2014, 29, 59-74.	3.1	175
16	Pygo2 regulates β -catenin-induced activation of hair follicle stem/progenitor cells and skin hyperplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10215-10220.	3.3	21
17	Chromatin Effector Pygo2 Mediates Wnt-Notch Crosstalk to Suppress Luminal/Alveolar Potential of Mammary Stem and Basal Cells. <i>Cell Stem Cell</i> , 2013, 13, 48-61.	5.2	75
18	Pygo2 regulates histone gene expression and H3 K56 acetylation in human mammary epithelial cells. <i>Cell Cycle</i> , 2012, 11, 79-87.	1.3	25

#	ARTICLE	IF	CITATIONS
19	A WNTer Revisit: New Faces of β^2 -Catenin and TCFs in Pluripotency. <i>Science Signaling</i> , 2011, 4, pe41.	1.6	20
20	Winning WNT: Race to Wnt signaling inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5929-5930.	3.3	35
21	Epithelial stem cells: An epigenetic and wntâ€centric perspective. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 1279-1287.	1.2	27
22	Cripto-1 Is a Cell Surface Marker for a Tumorigenic, Undifferentiated Subpopulation in Human Embryonal Carcinoma Cells. <i>Stem Cells</i> , 2010, 28, 1303-1314.	1.4	57
23	Intercellular transfer regulation of the paracrine activity of GPI-anchored Cripto-1 as a Nodal co-receptor. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 108-113.	1.0	12
24	Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. <i>Journal of Cell Biology</i> , 2009, 187, 343-353.	2.3	52
25	Neuronal Guidance Protein Netrin-1 Induces Differentiation in Human Embryonal Carcinoma Cells. <i>Cancer Research</i> , 2009, 69, 1717-1721.	0.4	16
26	Cripto-1 Is Required for Hypoxia to Induce Cardiac Differentiation of Mouse Embryonic Stem Cells. <i>American Journal of Pathology</i> , 2009, 175, 2146-2158.	1.9	54
27	Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. <i>Blood</i> , 2009, 113, 4810-4818.	0.6	126
28	Role of the EGF-CFC Family in Mammary Gland Development and Neoplasia. , 2009, , 87-102.		0
29	Regulation of human criptoâ€ gene expression by TGFâ€ ¹ and BMPâ€ ⁴ in embryonal and colon cancer cells. <i>Journal of Cellular Physiology</i> , 2008, 215, 192-203.	2.0	42
30	Netrinâ€ can affect morphogenesis and differentiation of the mouse mammary gland. <i>Journal of Cellular Physiology</i> , 2008, 216, 824-834.	2.0	24
31	Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. <i>Cell Biology International</i> , 2008, 32, 814-826.	1.4	18
32	Activation of a Nodalâ€independent signaling pathway by Criptoâ€ mutants with impaired activation of a Nodalâ€dependent signaling pathway. <i>FEBS Letters</i> , 2008, 582, 3997-4002.	1.3	13
33	Smad2 functions as a co-activator of canonical Wnt/ β^2 -catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. <i>Cellular Signalling</i> , 2008, 20, 1632-1641.	1.7	48
34	Characterization of the glycosylphosphatidylinositol-anchor signal sequence of human Cryptic with a hydrophilic extension. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2008, 1778, 2671-2681.	1.4	8
35	Regulation of Cripto-1 Signaling and Biological Activity by Caveolin-1 in Mammary Epithelial Cells. <i>American Journal of Pathology</i> , 2008, 172, 345-357.	1.9	23
36	Growth Factor Induction of Cripto-1 Shedding by Glycosylphosphatidylinositol-Phospholipase D and Enhancement of Endothelial Cell Migration. <i>Journal of Biological Chemistry</i> , 2007, 282, 31643-31655.	1.6	60

#	ARTICLE	IF	CITATIONS
37	Requirement of Glycosylphosphatidylinositol Anchor of Cripto-1 for trans Activity as a Nodal Co-receptor. <i>Journal of Biological Chemistry</i> , 2007, 282, 35772-35786.	1.6	51
38	β-Catenin/TCF/LEF regulate expression of the short form human Cripto-1. <i>Biochemical and Biophysical Research Communications</i> , 2007, 355, 240-244.	1.0	36
39	Multiple processing forms and their biological activities of a novel angiogenesis inhibitor vasohibin. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 640-646.	1.0	48
40	Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 919-925.	1.0	60
41	Isolation and Characterization of Vasohibin-2 as a Homologue of VEGF-Inducible Endothelium-Derived Angiogenesis Inhibitor Vasohibin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1051-1057.	1.1	81
42	Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5158-5164.	3.2	79
43	Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 327, 700-706.	1.0	84
44	Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. <i>Journal of Clinical Investigation</i> , 2004, 114, 898-907.	3.9	257
45	Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. <i>Journal of Clinical Investigation</i> , 2004, 114, 898-907.	3.9	141